Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS

Who May Qualify: - Adult patients admitted to the centers that will be part of the study - Infected by the HIV, regardless of the use of antiretroviral therapy - Patients diagnosed with disseminated histoplasmosis, confirmed by classical mycological methods (microscopy, culture or histopathology) or urinary Histoplasma antigen detection - Patients with central nervous system (CNS) infection may be included if they have an alternative diagnosis suggestive of another CNS infection - Patients using fluconazole for oroesophageal candidiasis may be included Who Should NOT Join This Trial: - Refusal to participate in the trial - Previous diagnosis of histoplasmosis - Pregnant or lactating women - Patients with renal failure at any given time (serum creatinine \> 2x or upper limit of normality (KDIGO, 2012) - Previous severe reaction to a polyene antifungal - Receipt of more than one dose of a polyene antifungal in the last 48 h - Suspected histoplasmosis involving the central nervous system - Patients who, in the judgment of the attending physician, have the prospect of death within the next 48 hours after selection, will also be excluded - Patients with suspected histoplasmosis involving the central nervous system (CNS), as this condition requires high doses of amphotericin B - Patients with the prospect of death in the next 48 hours after selection - Patients with a concomitant diagnosis of cryptococcus will be excluded, as will patients with leishmaniasis in treatment or in secondary prophylaxis with amphotericin - Patients without the capacity to administer enteral medication-at the discretion of the principal investigator of each center-considering that these patients will not be able to use itraconazole orally or through a feeding tube Always talk to your doctor about whether this trial is right for you.